Quarterly report pursuant to Section 13 or 15(d)

RELATED PARTY TRANSACTIONS (Details Narrative)

v3.7.0.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 26, 2017
Dec. 05, 2016
May 07, 2012
Jun. 30, 2015
May 31, 2014
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2016
Nov. 12, 2015
Sep. 30, 2015
Mar. 02, 2015
Notes payable - related parties, current portion           $ 292,863   $ 292,863           $ 297,820      
Exercise price of warrants           $ 0.28   $ 0.28           $ 0.29      
Beneficial conversion feature               $ 442,000                
Dr. David Platt [Member]                                  
Advance from related party                         $ 257,820        
Interest rate                         6.50%        
Notes payable - related parties, current portion           $ 297,820   297,820                  
Offsetting reimbursement amount against accrued interest                                 $ 82,355
Accrued interest to related party           $ 29,408   29,408           $ 35,542      
Dr. David Platt [Member] | Separation Agreement [Member]                                  
Milestone separation benefits                     $ 1,000,000            
Reimbursement amount for indemnification                     150,000            
Payment of outside legal expenses         $ 50,000                        
Expense associated with indemnification                   $ 63,296 $ 119,401            
Recognized cost of indemnification         $ 182,697                        
Dr. David Platt [Member] | Promissory Notes [Member]                                  
Interest rate     6.50%                            
Proceeds from promissory notes     $ 40,000                            
Advance Pharmaceutical Company Ltd. [Member] | Licensing And Manufacturing Agreement [Member]                                  
Revenue generated from agreement               $ 0                  
Advance Pharmaceutical Company Ltd. [Member] | Licensing And Manufacturing Agreement [Member] | Private Placement [Member]                                  
Number of shares issued                       1,799,800 1,799,800        
CJY Holdings Limited [Member]                                  
Number of shares issued   1,194,440                              
Proceeds from warrant exercises       $ 200,000                          
Reduction in exercise price of warrants                             0.17    
CJY Holdings Limited [Member] | Minimum [Member]                                  
Exercise price of warrants                             $ 0.50    
CJY Holdings Limited [Member] | Maximum [Member]                                  
Exercise price of warrants                             $ 1.00    
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member]                                  
Interest rate               10.00%                  
Face amount             $ 750,000   750,000                
Conversion price (in dollars per share)           $ 0.05   $ 0.05                  
Beneficial conversion feature               $ 1,642,000                  
Amortization of the beneficial conversion feature           $ 154,665 143,369 $ 309,330 261,023                
Bridge financing                               $ 1,600,000  
Maturity date description               August 2018                  
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | 6% Subordinated Convertible Debenture [Member]                                  
Proceeds from promissory notes $ 200,000                                
Beneficial conversion feature 186,939                                
Amortization of the beneficial conversion feature $ 16,645                                
Warrants issued 500,000                                
Warrant expiration period 5 years                                
Description of conversion feature

The conversion price is subject to adjustment for stock dividends and stock splits. In addition, if after the original issue date of the Debentures, either (i) the volume weighted average price equals or exceeds $0.50 for 10 consecutive trading days or (ii) the Company elects to list a class of securities on a national securities exchange, the Company may cause CJY to convert all or part of the then outstanding principal amount of the Debentures plus, accrued but unpaid interest, liquidated damages and other amounts owed.

                               
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | 6% Subordinated Convertible Debenture [Member] | Warrant [Member]                                  
Number of shares issued 2,000,000                                
Share price (in dollars per share) $ 0.10                                
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | Agreement 2015 [Member]                                  
Face amount             $ 1,200,000   $ 1,200,000                
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | Agreement 2016 [Member]                                  
Face amount           $ 1,752,000   $ 1,752,000                  
CJY Holdings Limited [Member] | Securities Purchase Agreement [Member] | Maximum [Member] | 6% Subordinated Convertible Debenture [Member]                                  
Exercise price of warrants $ 0.10                                
Face amount $ 1,000,000                                
Conversion price (in dollars per share) $ 0.10                                
Interest rate 10.00%